Gretchen E. White, PhD, assistant professor of Medicine in the Division of General Internal Medicine, was the study's first author.
Joining Dr. White on the study from the Division of Endocrinology and Metabolism at UPMC were David A. Rometo, MD, clinical associate professor of Medicine and clinical lead of the Endocrine Obesity Unit and Weight Management Program, and Mary Korytkowski, MD, emeritus professor of Medicine and prior director of Quality Improvement in the Division.
Evinacumab in Severe Hypertriglyceridemia with or without Lipoprotein Lipase Pathway Mutations: A Phase 2 Randomized Trial | UPMC Physician Resources
In collaboration with colleagues from other institutions, Erin Kershaw, MD, chief, UPMC Division of Endocrinology and Metabolism, and David Whitcomb, MD, PhD, professor emeritus, UPMC Division of Gastroenterology, Hepatology, and Nutrition, published a notable research article in Nature Medicine. Researchers evaluated evinacumab, a medication used to lower triglycerides, across three cohorts of patients with severe hypertriglyceridemia (sHTG).
Anti-Obesity Medications in the Pipeline: Phase-3 Clinical Trial | UPMC Physician Resources
The UPMC Divisions of Endocrinology and Metabolism, Minimally Invasive Bariatric and General Surgery, and Cardiology are collaborating as a site for TRIUMPH-3. This phase-3 multinational multi-site trial will evaluate the weight loss and cardiovascular event outcomes of Retatrutide, a triple agonist, stimulating the GLP-1, GIP, and Glucagon receptors as a weekly subcutaneous injection.
